Abstract
Glioma is the most common primary malignant brain tumor with a poor survival rate. It is characterized by diffuse and invasive growth and heterogeneity, which limits tumor identification and complete resection. Therefore, the precise detection and postoperative adjuvant therapy of gliomas have become increasingly important and urgent. Nanotechnology, with its excellent biocompatibility and controllable chemical properties, has attracted much attention in recent decades. Metal nanoparticles are widely used in the field of biomedical imaging and detection, and have shown promising applications in targeted drug delivery and therapy. This review summarizes the application of different types of metal nanoparticles in the treatment and detection of glioma, discussing the advantages and mechanisms of chemotherapy, radiotherapy, and photothermal therapy.
Introduction: The Challenge of Glioma
Glioma, particularly Glioblastoma Multiforme (GBM), remains one of the most devastating diagnoses in oncology, with a median survival rate of less than 15 months. The clinical challenge is three-fold:
- Invasiveness: Gliomas grow diffusely, making complete surgical resection nearly impossible.
- The Blood-Brain Barrier (BBB): This physiological barrier prevents over 98% of small-molecule drugs from entering the brain.
- Resistance: Standard chemotherapy and radiotherapy often fail because tumor cells develop robust mechanisms to survive DNA damage.
Metal nanoparticles (NPs) offer a potential solution by acting as a "Trojan Horse," sneaking therapeutic payloads past the BBB and utilizing their inherent metallic properties to amplify the effects of traditional treatments.
Strategic Pillars of Nanoparticle Intervention
The review categorizes nanoparticle intervention into three strategic pillars designed to overcome traditional treatment limitations:
- Passive vs. Active Targeting: Utilizing the Enhanced Permeability and Retention (EPR) effect for passive accumulation, or surface-functionalizing NPs with ligands (like Angiopep-2 or folic acid) to actively bind to receptors overexpressed on glioma cells.
- Physical Stimulation: Using external triggers—such as magnetic fields for hyperthermia, Near-Infrared (NIR) light for photothermal therapy, and X-rays for radiosensitization.
- Surface Engineering: Employing biocompatible coatings like Polyethylene Glycol (PEG) to increase blood circulation time and reduce immune clearance.
Key Insights: Physics-Based Precision
A significant shift in glioma treatment is the move toward physics-based therapeutic nanoparticles. High atomic number (Z) metals like Gold (Au) are not merely carriers; they are active participants in radiotherapy. When irradiated by X-rays, they produce secondary Auger electrons that cause localized, lethal DNA damage to tumor cells, effectively concentrating the radiation dose within the tumor.
Furthermore, Magnetic Iron Oxide NPs (MNPs) serve a unique "triple-threat" role. They act as MRI contrast agents for imaging, can be guided to the tumor using external magnets, and can be vibrated by alternating magnetic fields to generate localized heat (hyperthermia) that kills cancer cells.
Clinical Progress and Results
Recent literature highlights several quantitative milestones in the development of these technologies:
- Survival Extension: Gold nanoparticles loaded with doxorubicin have shown significantly prolonged median survival times in glioma-bearing mouse models compared to free drug delivery.
- Targeting Efficiency: Peptide-modified gold NPs demonstrated accumulation levels in glioblastoma 1.5 times higher than unmodified versions.
- Radiosensitization: Silver (Ag) NPs enhance the radiosensitivity of U251 glioma cells even at concentrations as low as one-tenth of their typical inhibitory dose.
- Clinical Translation: Several nano-formulations are currently in clinical trials, including AGuIX (gadolinium-based NPs for radiotherapy enhancement) and NU-0129 (spherical nucleic acid gold nanoparticles).
Limitations and Future Outlook
Despite the promise of metal nanoparticles, significant hurdles remain. Long-term toxicity and the bioaccumulation of metals in the liver, spleen, and brain are not yet fully understood. Additionally, the complexity and cost of manufacturing multifunctional NPs with consistent quality hinder mass production.
The future of the field lies in "Smart Nanoplatforms"—particles designed to release their payload only in response to the specific acidic or enzymatic microenvironment of a tumor, further minimizing side effects on healthy brain tissue and moving closer to personalized precision medicine.
Summary updated